SmithKline-Beecham's Coreg reduces CHF mortality by 67% in trial -- AHA meeting.
Executive Summary
SMITHKLINE BEECHAM COREG (CARVEDILOL) DECREASES MORTALITY BY 67% in patients with mild to severe congestive heart failure, according to data from a multi-center trial presented at the American Heart Association's 68th Scientific Sessions in Anaheim, California Nov. 13. The mortality rate in the carvedilol arm was 3% (21/696) compared to 7.8% (31/398) in placebo. The risk reduction was similar across CHF severity, Packer reported. Risk reduction among Class II patients using carvedilol was 68% (2.4% mortality in carvedilol vs. 5.8% mortality in placebo) while risk reduction in Class III-IV was 67% (3.7% vs. 10%).